Prilocard 1.25 mg tablets for dogs

Negara: Irlandia

Bahasa: Inggris

Sumber: HPRA (Health Products Regulatory Authority)

Beli Sekarang

Karakteristik produk Karakteristik produk (SPC)
12-06-2017

Bahan aktif:

Ramipril

Tersedia dari:

aniMedica GmbH

Kode ATC:

QC09AA05

INN (Nama Internasional):

Ramipril

Dosis:

1.25 mg/tablet

Bentuk farmasi:

Tablet

Jenis Resep:

POM: Prescription Only Medicine as defined in relevant national legislation

Kelompok Terapi:

Dogs

Area terapi:

ramipril

Indikasi Terapi:

Cardiovascular

Status otorisasi:

Authorised

Tanggal Otorisasi:

2012-07-13

Karakteristik produk

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Prilocard 1.25 mg tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Active substance:
Ramipril 1.25 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablets.
White round biconvex tablets, imprinted with ‘B’ on one side of
the tablet and ‘48’ on the other.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For treatment of congestive heart failure (equivalent to New York
Heart Association [NYHA] classes II,
III and IV)
caused by valvular
insufficiency due to endocardiosis or
cardiomyopathy.
The preparation may if
applicable be
administered concomitantly with furosemide (diuretic) and/or the
cardiac glycosides digoxin or methyl digoxin.
In patients treated concomitantly with ramipril and furosemide, the
diuretic dose may be reduced to achieve the same
diuretic effect as in treatment with furosemide alone.
4.3 CONTRAINDICATIONS
Do not
use in haemodynamically-related stenoses (e.g.
aortic stenosis,
mitral
stenosis)
nor
in cases of
obstructive
hypertrophic cardiomyopathy.
Do not use in cases of hypersensitivity to the active substance,
ACE-inhibitors or to any of the excipient(s).
See Section 4.7 for use in Pregnancy and Lactation
Class
Clinical symptoms
II
Fatigue, dyspnoea, cough etc. seen in normal activity.
Ascites may occur at this stage.
III
Comfortable at rest, but capacity for activity minimal.
IV
Incapable of any activity.
Clinical symptoms of disablement occur even at rest.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___

                                
                                Baca dokumen lengkapnya
                                
                            

Peringatan pencarian terkait dengan produk ini